Biofabri and TBVI sign an agreement with the European Commission to accelerate the final development of the MTBVAC vaccine.
Advertising
Tuberculosis affects 10 million people each, and drug-resistant tuberculosis is a growing problem, with more than 400,000 new cases and more than 150,000 deaths each year. Finding a defense against this infection is no easy task.
Zenda l Group, through its subsidiary Biofabri, and TBVI (a European non-profit foundation that promotes the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people) have signed a contract with the European Executive Agency for Health and Digital Agenda (HaDEA) under the EU4Health program to accelerate the final development of the MTBVAC vaccine.
